You can buy or sell RGLS and other stocks, options, ETFs, and crypto commission-free!
Regulus Therapeutics Inc. Common Stock, also called Regulus Therapeutics, is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Read More Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Expected Mar 16, After Hours